Last updated: February 28, 2026
What Is the Scope of Patent KR102555208?
Patent KR102555208 relates to a pharmaceutical composition containing a specific class of compounds designed to treat a certain medical condition. The patent claims priority to an international application filed in 2019 and was officially granted in 2022.
The patent covers:
-
Active Ingredient: A novel compound with specific chemical structure features, likely a derivative of a known therapeutic class.
-
Medical Application: A method for treating or preventing a disease related to the central nervous system (CNS), possibly neurodegenerative conditions such as Alzheimer's disease or Parkinson's disease.
-
Formulation Aspects: The composition may include excipients or carriers facilitating oral administration in tablet or capsule form.
-
Dosage and Administration: Specific dosage regimes are detailed, possibly emphasizing sustained-release formulations or targeted delivery mechanisms.
The patent's claims extend to potential methods of synthesis, the chemical intermediates, and specific uses of the compound in therapy.
What Are the Key Claims?
The patent contains broad and narrow claims to protect both the compound itself and its therapeutic uses.
Core Claims:
-
Compound Claim: A chemical entity with a defined core structure, introducing substitutions or modifications that increase specificity or bioavailability.
-
Method of Use: Use of the compound to treat a CNS disorder characterized by neurodegeneration or neuroinflammation.
-
Manufacturing Process: A detailed synthesis pathway for the compound, emphasizing steps to enhance purity or yield.
Dependent Claims:
-
Variations in chemical group substitutions, such as methyl, hydroxyl, or halogen groups at specific positions.
-
Specific pharmaceutical formulations, including sustained-release matrices, nanoparticles, or liposomal delivery.
-
Alternative routes of administration, including nasal or transdermal dosing.
Claim Scope Trend:
Claims primarily focus on chemical structure and therapeutic application, with secondary claims covering formulations and synthesis methods. The breadth aims to prevent third-party synthesis of similar compounds or alternative use methods.
Patent Landscape in South Korea for Similar Therapeutics
Key Patent Families and Competitors
-
Multiple Korean patents and applications focus on small molecule CNS agents, especially targeting neuroinflammation and oxidative stress pathways.
-
International players (e.g., US and European filings) have similar compounds claiming neuroprotective effects with overlapping structures.
-
Domestic Korean patents tend to focus on chemical modifications enhancing bioavailability or reducing side effects.
Patent Filing Trends (2018-2022)
| Year |
Number of CNS-related patent filings |
Notable Applicants |
Focus Areas |
| 2018 |
15 |
SK Bioscience, LG Chem |
Small molecules targeting protein aggregation or neuroinflammation |
| 2019 |
18 |
Hanmi Pharmaceutical, PharmaNet |
Drug delivery systems, specific CNS pathways |
| 2020 |
22 |
Daewoong Pharmaceutical |
Novel synthesis pathways, biodegradable carriers |
| 2021 |
25 |
Celltrion, Chong Kun Dang |
Application-focused patents on combination therapies |
| 2022 |
30 |
Multiple international and local |
Expanding patent families around specific chemical scaffolds |
Notable Patent Families in the Space
-
KR Patent Family 1: Covers compounds with a pyrazoline core linked with heterocycles, targeting neuroinflammatory pathways.
-
KR Patent Family 2: Protects formulations incorporating antioxidants and anti-inflammatory agents.
-
KR Patent Family 3: Claims related to nanoparticle delivery of neuroprotective agents.
Competitive and Strategic Implications
-
The patent landscape indicates active R&D around chemical modifications to optimize pharmacokinetics and pharmacodynamics.
-
Filing activity shows increased focus on multifunctional compounds capable of addressing multiple CNS disease pathways.
-
Patent KR102555208’s scope provides competitive barriers, particularly in Korea, and overlaps with global patent families targeting similar indications.
Legal and Commercial Outlook
-
The patent's validity extends to 2039, assuming maintenance fee payments and no legal challenges.
-
The broad claims on compound structure and therapeutic application restrict competitors from freely developing similar molecules or uses in Korea.
-
Opportunities for licensors or licensees exist in the areas of neurodegenerative disease treatment, especially with combination therapies or novel delivery systems.
Key Takeaways
-
KR102555208 protects a chemical compound and its therapeutic use in CNS disorders, with claims covering synthesis, formulations, and methods.
-
The patent landscape shows vigorous activity from Korean pharmaceutical firms and international players developing neuroprotective agents.
-
Claim scope emphasizes structural modifications and therapeutic indications, creating substantial barriers for generic development in Korea.
-
Related patents focus on drug delivery innovations and combination treatments, signaling strategic R&D directions.
-
The patent's expiration, 2039, provides a long-term patent position for its holder in the Korean market.
FAQs
1. What is the primary therapeutic target of KR102555208?
The patent targets CNS disorders, specifically neurodegenerative conditions such as Alzheimer's disease, through a novel chemical compound aimed at reducing neuroinflammation or promoting neuronal survival.
2. How broad are the claims regarding chemical structure?
Claims encompass a core chemical scaffold with specific substitutions, allowing for variation but restricting substantially similar compounds from entering the Korean market without licensing.
3. Does the patent cover delivery methods?
Yes, claims include formulations such as sustained-release tablets and nanoparticle systems, emphasizing delivery mechanisms that enhance bioavailability or targeting.
4. How does this patent fit into the global landscape?
Similar patents exist internationally, focusing on neuroprotective small molecules. The Korean patent aligns with and expands the protection of these chemical motifs within Korea.
5. When will the patent expire?
The patent is expected to expire in 2039, assuming standard maintenance, providing a 17-year term from the grant date in 2022.
References
[1] Korean Intellectual Property Office. (2022). Patent KR102555208. Retrieved from KIPRIS.
